AstraZeneca US trial shows 79% efficacy against Covid-19 pandemic

Trial found no increased risk of blood clots

AstraZeneca’s coronavirus vaccine fared better than expected in a US clinical trial, providing reassurance about its safety and efficacy.

The shot developed with the University of Oxford was 79 per cent effective in preventing Covid-19, and an independent monitoring board found no safety concerns, the company said Monday. All those immunised were protected from severe disease and death in a study of more than 30,000 volunteers.

The findings should bolster confidence in the vaccine after confusion over its efficacy and the best dosing regimen slowed take-up. The product is at the center of a supply showdown with the European Union just days